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The primary tumour location is an important prognostic factor for previously untreated metastatic 
colorectal cancer (mCRC). However, the predictive efficacies of primary tumour location, early tumour 
shrinkage (ETS), and depth of response (DpR) on mCRC treatment has not been fully evaluated. This 
study aimed to investigate the predictive efficacies of these traits in mCRC patients treated with first‑
line 5‑fluorouracil‑based chemotherapy plus biologic agents, namely, cetuximab and bevacizumab. 
This was a retrospective analysis of the medical records of 110 patients with pathology‑documented 
unresectable mCRC. Patients with left‑sided mCRC receiving any first‑line regimen showed better 
overall survival (OS) than those with right‑sided mCRC [33.3 vs 16.3 months; hazard ratio (HR) 0.44; 
95% confidence interval (CI) 0.27–0.74; p < 0.001]. In patients with left‑sided tumours, treatment 
with chemotherapy plus cetuximab yielded longer OS than chemotherapy plus bevacizumab (50.6 vs 
27.8 months, HR 0.55; 95% CI 0.32–0.97; p = 0.0378). mCRC patients with ETS and high DpR showed 
better OS than those lacking ETS and with low DpR (33.5 vs 19.6 months, HR 0.50, 95% CI 0.32–0.79, 
p = 0.023 and 38.3 vs 19.0 months, HR 0.43, 95% CI 0.28–0.68, p < 0.001, respectively). Moreover, ETS 
and/or high DpR achieved in patients with right‑sided mCRC receiving chemotherapy plus cetuximab 
were associated with significantly better OS than in those lacking ETS and with low DpR (34.3 vs 
10.4 months, HR 0.19, 95% CI 0.04–0.94, p = 0.025 and 34.3 vs 10.4 months, HR 0.19, 95% CI 0.04–
0.94, p = 0.0257, respectively). Taken together, our study demonstrates that primary tumour location 
is not only a well‑known prognostic factor but also a relevant predictive factor in patients with mCRC 
receiving chemotherapy plus cetuximab. Additionally, both ETS and DpR could predict treatment 
outcomes and also potentially guide cetuximab treatment even in right‑sided mCRCs.
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths  worldwide1. However, with advances 
in chemotherapeutic and biologic agents, diagnosis, and ablative techniques, the survival of patients with unre-
sectable metastatic CRC (mCRC) has improved from 12 to over 30  months2. The standard first-line therapy for 
mCRC includes 5-fluorouracil plus folic acid combined with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX)3. 
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Further, in previous Phase-III randomised trials, compared to the FOLFIRI or FOLFOX regimen, administra-
tion of either an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (cetuximab and panitu-
mumab) or an anti-vascular endothelial growth factor (VEGF) antibody (bevacizumab) showed favourable OS, 
progression-free survival (PFS), and overall response rate (ORR) in the patients with CRC 4–6. However, when the 
efficacies of combination therapies of cetuximab or bevacizumab with FOLFIRI or FOLFOX were compared, the 
outcomes were controversial. The FIRE-3 study randomised mCRC patients with KRAS exon 2 wild-type (wt) 
status into either FOLFIRI plus cetuximab or bevacizumab groups and the median OS was found to be better 
upon treatment with FOLFIRI plus  cetuximab7. In contrast, Venook et al. in their CALGB/SWOG 80,405 study 
observed no significant difference in OS upon administration of cetuximab vs bevacizumab compared to the 
FOLFOX or FOLFIRI regimen for the treatment of patients with KRAS wt, advanced CRC or mCRC 8. Therefore, 
a detailed analysis is required to comprehend the efficacy of either treatment modalities.
Several studies have embarked upon identifying prognostic and predictive factors for targeted therapy using 
anti-EGFR antibodies in patients with mCRC. The anti-EGFR antibody did not show any clinical benefits for 
patients with any RAS  mutation9,10. Therefore, it is essential to confirm the mutational status of RAS before 
administering anti-EGFR therapy to patients with mCRC. Furthermore, while the V600E BRAF mutation is a 
negative prognostic marker for mCRC, its utility in predicting response to anti-EGFR therapy is still  uncertain11. 
The HER2 status may impact the response to anti-EGFR therapies since its activation substitutes EGFR depend-
ence in a subset of mCRC patients, thus serving as a potentially negative predictor of the beneficial effects of 
anti-EGFR  therapy12.
In contrast, the primary tumour location has been shown to predict prognosis in patients with previously 
untreated mCRC 13, supported by post hoc analyses of large randomised controlled trials and meta-analyses. 
Holch et al.14 reported that in patients receiving bevacizumab and cetuximab, tumours originating in the right-
side were associated with higher mortality than left-sided tumours. Additionally, several studies found the 
primary tumour location to be predictive of response to anti-EGFR therapy, although only in patients with a 
left-sided tumour harbouring a RAS wt  status15–17. Furthermore, in the pooled analysis of six randomised trials, 
mCRC patients with left-sided tumours harbouring RAS wt status showed favourable ORR, OS, and PFS than 
those with right-sided tumours, and the analyses predicted better response upon treatment with chemotherapy 
plus anti-EGFR therapy than chemotherapy alone or chemotherapy plus anti-VEGF  therapy18. Taken together, 
these findings suggest that the location of tumours on the left side can help predict the efficacy of anti-EGFR 
antibodies in mCRC patients with KRAS wt status.
Recent retrospective analyses of clinical trial data have included early tumour shrinkage (ETS) and depth 
of response (DpR) as measures for assessing tumour  response3,19,20. While ETS offers an early indication of 
sensitivity to treatment and is associated with improved PFS and OS irrespective of the treatment received, the 
DpR reveals the maximum tumour shrinkage achieved, which relates to the post-progression survival. However, 
their clinical relevance has not been firmly established, and there are limited data on these response assessments 
according to primary tumour location.
The studies presented above are retrospective analyses of randomised clinical trials, majorly conducted in 
western nations, and their outcomes cannot be generalised to patients in actual clinics. Therefore, here, we inves-
tigated the prognostic and predictive efficacy of primary tumour location and the impact of ETS and/or DpR on 
therapeutic outcomes in a cohort of patients with mCRC treated with first-line chemotherapy plus bevacizumab 
or cetuximab in the real-world setting in a Japanese population.
Results
Patient characteristics. Based on the eligibility criteria, 110 patients with mCRC, who received first-line 
treatment were included in the study (Fig. 1). The patient characteristics based on the location of the primary 
tumour, are summarised in Table 1. There were 76 (69.1%) patients with left-sided and 34 (30.9%) with right-
sided mCRC. Overall, the clinical characteristics of the patients, such as KRAS (RAS) status, tumour condition 
(advance or recurrence), comorbidity (with or without), and primary tumour status (resection or no resection), 
were comparable in the left-sided and right-sided tumours. However, significant differences were observed in 
the histological statuses, with 72 of the 76 left-sided tumours classified as adenocarcinoma (94.7%), whereas 
10 of the 34 right-sided tumours were mucinous (29.4%). Further, the oxaliplatin-based regimen was the most 
widely used chemotherapy (70 of 110 patients, 63.6%), although no significant differences were observed 
between irinotecan-based and oxaliplatin-based regimens for the treatment of left- and right-sided tumours. 
Additionally, bevacizumab-containing chemotherapy was preferred over cetuximab-containing regimen (60 of 
110 (54.5%) vs 50 of 110 (45.5%) patients, respectively). However, no significant differences were noted for the 
use of biological agents between left- and right-sided tumours. Furthermore, 46 of 60 patients (76.7%) receiving 
bevacizumab had KRAS mutation.
Efficacy of outcome based on primary tumour location and molecular‑targeted agents. The 
ORR observed for all the patients was 66 (60%), of which 4 showed complete response (3.6%) and 62 showed 
partial response (54.6%). Left-sided tumours showed significantly higher ORR than the right-sided tumours 
(67.1% vs 44.1%; p = 0.003, Table  2). Further, no significant differences were observed upon treatment with 
chemotherapy plus cetuximab or bevacizumab in patients with either left- or right-sided tumours (Table 2). 
Moreover, the ORR did not vary upon treatment with cetuximab or bevacizumab (66.0% vs 55.5%, Table S1). 
Additionally, while the difference between the ORR of left- and right-sided tumours upon treatment with chem-
otherapy plus bevacizumab was not significant (p = 0.596), treatment with cetuximab conferred better ORR in 
patients with left-sided tumours (77.8%) than in those with right-sided tumours (35.7%, p = 0.008, Table S1).
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Assessment of progression‑free survival and overall survival based on the primary tumour 
location. Overall, the median PFS, median OS and median follow-up duration of all the patients combined 
was 11.4, 27.8, and 25.1 (range 1.8–103.2) months, respectively.
Comparison of the primary tumour location suggested significantly better median PFS (12.7 vs 6.8 months; 
HR 0.63; 95% CI 0.41‒0.97; p = 0.035) (Fig. 2A), and median OS (33.3 vs 16.3 months; HR 0.44; 95% CI 
Database search (n = 226)
Patients with mCRC 
receiving first-line 
chemotherapy
Excluded from analysis (n = 116)
Not treated with FOLFOX or FOLFIRI: 40
Not treated with cetuximab or bevacizumab: 31
PS ≥ 3: 15
Tumour of undetermined origin: 2



















Figure 1.  Flow diagram indicating patient details. mCRC metastatic colorectal cancer.
Table 1.  Patient characteristics and treatments grouped based on primary tumour sites. a All patients receiving 
cetuximab were confirmed for KRAS wt or RAS wt.
All (n = 110) Left-sided (n = 76) Right-sided (n = 34) p value
Age (years), median (range) 65 (23–84) 63 (30‒82) 67 (23‒84)
Gender 0.064
Male, n (%) 54 (49) 42 (55.3) 12 (32.4)
Female, n (%) 56 (51) 34 (44.7) 22 (67.6)
Comorbidity 0.889
Yes 7 (6.4) 5(6.6) 2 (5.9)
No 103 (93.6) 71 (93.4) 32 (94.1)
Histologic type 0.001
Adenocarcinoma, n (%) 96 (87.3) 72 (94.7) 24 (70.6)
Mucinous, n (%) 14 (12.7) 4 (5.3) 10 (29.4)
KRAS (RAS) statusa 0.144
KRAS (RAS) wild/mutant, n 64 (11)/46 48 (7) / 28 16 (4) / 18
Condition 0.227
Advanced, n (%) 85 (77.3) 56 (73.7) 29 (85.3)
Recurrent, n (%) 25 (22.3) 20 (26.3) 5 (14.7)
Primary tumour 0.831
Resection, n (%) 70 (63.6) 49 (64.5) 21 (61.8)
No Resection, n (%) 40 (36.4) 27 (35.5) 13 (38.2)
Doublet chemotherapy 0.392
Oxaliplatin base, n (%) 70 (63.6) 46 (60.5) 24 (70.6)
Irinotecan base, n (%) 40 (36.4) 30 (39.5) 10 (29.4)
Type of biological agent
Bevacizumab, n (%) 60 (54.5) 40 (52.6) 20 (58.8) 0.546
Cetuximab, n (%) 50 (45.5) 36 (47.4) 14 (41.2)
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0.27‒0.74; p < 0.001) (Fig. 2B) in patients with left-sided tumours than in those with right-sided tumours, 
respectively. Moreover, treatment of patients with left-sided tumours using cetuximab significantly prolonged 
the median OS than did bevacizumab (50.6 vs 27.8 months; HR 0.55; 95% CI 0.32‒0.97; p = 0.0378), although 
the difference in PFS was not significant (15.8 vs 11.9 months; HR 0.62; 95% CI 0.38‒1.01; p = 0.052) (Fig. 2C,D). 
Furthermore, treatment of patients with right-sided tumours using either cetuximab or bevacizumab did not 
follow the trend, and the differences in median PFS (6.8 vs 6.7 months; HR 1.03; 95% CI 0.49‒2.14; p = 0.926) 
and median OS (11.3 vs 19.5 months; HR 1.11; 95% CI 0.50‒2.44; p = 079) were not significant. (Fig. 2E,F).
Assessment of progression‑free survival and overall survival based on the biological therapy 
group. Next, we examined the PFS and OS of patients treated with cetuximab or bevacizumab (Fig. S1A,B). 
The PFS did not differ for patients treated with cetuximab (n = 50) or bevacizumab (n = 60) (12.6 vs 10.2 months, 
respectively; HR 0.68; 95% CI 0.45‒1.02; p = 0.061), and the OS followed a similar trend (38.0 vs 25.6 months, 
respectively; HR 0.65; 95% CI 0.41‒1.01; p = 0.0584). Further, we assessed the PFS and OS based on primary 
tumour location in patients treated with these agents (Fig. S1C-F). Our analysis suggests that patients with left-
sided tumours showed better median OS and PFS than those with right-sided tumours upon treatment with 
cetuximab (50.6 vs 11.3 months; HR 0.34; 95% CI, 0.16‒0.71; p = 0.0026), although the difference in PFS was 
not significant (15.8 vs 6.8 months; HR 0.60; 95% CI 0.30‒1.18; p = 0.136) (Fig. S1C,D). Furthermore, treat-
ment with bevacizumab resulted in better median PFS in patients with left-sided tumours than in those with 
right-sided tumours (11.9 vs 6.7 months, respectively; HR 0.70; 95% CI 0.40‒1.22; p = 0.234), along with better 
median OS (27.8 vs 19.0 months, respectively; HR 0.48; 95% CI 0.25‒0.90; p = 0.0199) (Fig. S1E, F).
Predictive value of the primary tumour location, ETS, and DpR. The data for tumour shrinkage 
from baseline till the 8th week was available for 110 patients with mCRC, and the patient outcome, including 
ETS and DpR, based on primary tumour location is summarised in Table 3. Seventy-one patients (64.5%) expe-
rienced ETS and showed significantly better OS than those who did not experience ETS (33.5 vs 19.6 months; 
HR 0.50; 95% CI 0.32‒0.79; p = 0.0023) (Fig. 3A).
In all the treatment arms, patients with left-sided tumours experienced ETS more than those with right-sided 
tumours (56 (73.7%) vs 15 (44.1%), respectively). Further, patients with left-sided tumours treated with cetuxi-
mab showed high ETS than those treated with bevacizumab (63.9% vs 52.5%, p = 0.065, Table 3), and patients 
with ETS also showed better OS, irrespective of treatment with either of the drugs (Fig. 3B,C).
In contrast, patients with right-sided tumours showed higher ETS when treated with bevacizumab than 
with cetuximab (50% vs 35.7%, p = 0.4, Table 3). However, patients treated with cetuximab that showed ETS 
presented with significantly better OS than those that did not experience ETS (34.3 vs 10.4 months; HR 0.19; 
95% CI, 0.04‒0.94; p = 0.025) (Fig. 3D), although the difference in OS was not significant (16.3 vs 19.5 months; 
HR 0.91; 95% CI 0.34‒2.47; p = 0.867) in patients with right-sided tumours treated with bevacizumab (Fig. 3E).
Next, the median DpR in patients with left-sided mCRCs receiving cetuximab and bevacizumab was − 43.5% 
(range − 100 to 30) and − 30.0% (range − 64 to 25), respectively (p = 0.001). On the other hand, the median DpR 
in patients with right-sided mCRCs receiving cetuximab and bevacizumab was − 9.6% (range − 100 to 45) and 
− 33% (range − 58 to 3), respectively (p = 0.42) (Table 3). The DpR of individual patients with left- and right-sided 
mCRCs treated with either cetuximab or bevacizumab are shown in Fig. 4. The maximal DpR was observed in 
a few patients with left- and right-sided mCRCs, and particularly, 5 patients who received chemotherapy plus 
cetuximab showed 100% reduction, and 2 of them underwent complete (R0) resection (Fig. 4A,B).
To evaluate the relationship between patient DpR and survival, we classified DpR into high and low groups 
based on the median DpR value (Fig. 5). The median DpR of all the treatment population was − 30 (range − 100 
to 45, Table 3), and patients with high DpR showed better OS than those with low DpR (38.3 vs 19.0 months; 
HR 0.43; 95% CI 0.28‒0.68; p < 0.001) (Fig. 5A). In the patients with right-sided tumours, the high DpR group 
showed better OS than the low DpR group when treated with cetuximab (34.3 vs 10.4 months, p = 0.0257) 
(Fig. 5D).
Table 2.  Efficacy for the first-line treatment in patients with mCRC stratified based on the molecular-
target agent and tumour location. CR complete response, PD progressive disease, PR partial response, RD 
recommended dose, SD stable disease, ORR overall response. *p value for difference between tumour side 
< 0.05.
Left-sided mCRC (n = 76) Right-sided mCRC (n = 34)
All Cetuximab (n = 36) Bevacizumab (n = 40) All Cetuximab (n = 14) Bevacizumab (n = 20)
CR 3 (4.3%) 3 (8.3%) 0 (0.0%) 1 (2.9%) 1 (7.1%) 0 (0.0%)
PR 48* (63.2%) 25 (69.4%) 23 (57.5%) 14* (41.2%) 4 (28.6%) 10 (50.0%)
SD 22 (28.9%) 6 (16.7%) 16 (40.0%) 16 (47.1%) 6 (42.9%) 10 (50.0%)
PD 3 (3.9%) 2 (5.6%) 1 (2.5%) 3 (8.8%) 3 (21.4%) 0 (0.0%)
ORR 51* (67.1%) 28 (77.8%) 23 (57.5%) 15* (44.1%) 5 (35.7%) 10 (50%)
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Discussion
Here, we enrolled a cohort of consecutive patients with mCRC in real-world clinical setting, and assessed fac-
tors known to affect their prognosis and treatment outcomes, such as primary tumour location, biologic therapy 
(bevacizumab or cetuximab), and the more recently proposed indicators, EST and DpR.
Our findings support the notion that primary tumour location is an important prognostic factor in mCRC 
and can help guide treatment decisions on the first-line regimen based on the findings that clinical benefits for 
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Treatment       Median (months)
Cetuximab 11.3
Bevacizumab 19.5
HR (95% CI), 1.11 (0.50‒2.44)
P = 0.79
Tumor location       Median (months)
Left-sided mCRC 33.3
Right-sided mCRC 16.3
HR (95% CI), 0.44 (0.27‒0.74)
P < 0.001
Tumor location       Median (months)
Left-sided mCRC 12.7
Right-sided mCRC 6.8
HR (95% CI), 0.63 (0.41‒0.97)
P = 0.035
Figure 2.  Kaplan–Meier analyses of mCRC samples based on tumour location. (A) Progression-free survival 
(PFS) and (B) overall survival (OS) for all the patients; (C) PFS and (D) OS in patients with left-sided mCRCs 
treated with chemotherapy plus cetuximab or bevacizumab; (E) PFS and (F) OS in patients with right-sided 
mCRCs treated with chemotherapy plus cetuximab or bevacizumab. CI confidence interval, HR hazard ratio.
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during treatment with first-line agents were associated with favourable outcomes in patients with mCRC, further 
supporting the use of these endpoints clinically. Furthermore, our study raises the possibility of a predictive 
relevance of ETS and DpR in guiding targeted therapy (cetuximab) in patients with right-sided mCRC.
First, our study demonstrated that patients with left-sided mCRC receiving chemotherapy plus cetuximab 
or bevacizumab showed better ORR, PFS, and OS than those with right-sided mCRC (Table 2; Fig. 2A,B), 
reconfirming previous evidence that primary tumour location serves as a prognostic factor for patients treated 
with any first-line  regimen13,14,17,18. Further, we observed an association between the primary tumour location 
and treatment with cetuximab, where patients with left-sided tumours showed better survival outcomes when 
treated with cetuximab than with bevacizumab (Fig. 2C,D). However, right-sided tumours responded differ-
ently and showed no significant difference in survival outcomes upon treatment with bevacizumab or cetuximab 
(Fig. 2E,F). Moreover, these observations were found to be corroborated by several randomised clinical trials 
that reported tumours on the left side as predictors of response to cetuximab, while those on the right side as 
non-responsive to cetuximab despite the RAS wt  status15,16,21,22.
Together, these observations suggest that mCRC is a heterogeneous disease with the primary tumours origi-
nating from different areas of the colon showing molecular  differences23. According to the CRC Subtyping Con-
sortium, consensus molecular subtype 2 (CMS2) is predominantly distributed in left-sided tumours and shows 
activated EGFR-dependent signalling defined by the over-expression of EGFR. Although right-sided tumours 
showed high proportions of the microsatellite unstable/immune CMS1 and the metabolic CMS3  subtypes24, 
these differences could be among the factors contributing to differential responses to treatment with cetuximab 
based on tumour  location25. However, the main genetic drivers and crucial factors contributing to the vast dif-
ferences remain largely unknown.
Further, since RAS is mutated (RAS mt) in about 55% of the mCRC cases, these patients need to be treated 
with  bevacizumab26. However, the majority of recently published studies with randomised trials have focused 
on the RAS wt subpopulation alone; hence, data on treatment with bevacizumab for RAS mt mCRC involving 
the two primary tumour locations are  limited16,27,28. Moreover, while several clinical studies have suggested that 
the tumour location does not predict benefit from bevacizumab treatment in patients with mCRC harbouring 
KRAS  wt16,29 and undetermined RAS  status30, other reports indicate better outcomes in left- than right-sided 
mCRC, with unselected RAS status, treated with  bevacizumab13,17,30. Our analysis suggests that patients treated 
with bevacizumab had the RAS mt-mCRC predominantly, and left-sided mCRCs were associated with better 
PFS and OS than right-sided mCRCs (Fig. S1E,F). Therefore, these findings suggest that the primary tumour 
location is closely associated with outcomes even in patients with RAS mt status treated with chemotherapy plus 
bevacizumab. However, further investigations would be required to determine whether the primary tumour 
location and treatment with chemotherapy plus bevacizumab is associated with different effects, especially in 
patients with RAS-mt mCRC.
Next, our analysis validated the previous observation that patients with ETS and high DpR show an improved 
OS than those without ETS and with low  DpR3,19,20. Further, we observed that the frequency of ETS was high in 
patients with left-sided mCRC than in those with right-sided mCRC. Moreover, patients with left-sided mCRC 
receiving cetuximab-based regimen showed a high frequency of ETS (Table 3), which may result in favourable 
OS than in those who did not show ETS and other groups (Fig. 3). Although limited data are available, especially 
comparing biologic agents, recent retrospective analysis of the PEAK  trail31, revealed that a high proportion 
of patients with left-sided mCRC achieved ETS and better OS when treated with panitumumab than bevaci-
zumab. Furthermore, the DpR is reported to be associated with a maximal response, which in turn relates to 
post-progression survival in  patients20. Consistent with this, we observed a high DpR in patients with left-sided 
mCRCs receiving cetuximab, along with a complete reduction in tumour content in 4 of 36 patients (Fig. 4A) 
and significantly better OS in the high DpR than in the low DpR groups (Fig. 5A). Additionally, although the 
median DpR was low in the patients with right-sided mCRCs receiving cetuximab (Table 3), few patients had a 
high response rate (Fig. 4B), and those with high DpR showed significantly better OS than those with low DpR 
(Fig. 5D). Interestingly, our analysis suggested that patients with ETS also presented with significantly better OS 
than those without ETS (Fig. 3A) and with right-sided mCRCs receiving cetuximab (Fig. 3D), consistent with 
the findings of the PEAK  trial31. Taken together, these findings suggest that the ETS/DpR may help identify a 
subgroup of patients with right-sided tumours who may achieve improved outcomes. Further, the guidelines of 
the NCCN clinical practice for Colon cancer, version 4. 2020, recommend anti-EGFR monoclonal antibody for 
the treatment of patients with KRAS/NRAS wt status and left-sided mCRC alone. However, our analysis indicated 
that administering bevacizumab might not be the only treatment option in patients with right-sided mCRCs 
harbouring RAS wt and that cetuximab might be considered in a certain subtype of mCRC with ETS and/or high 
Table 3.  Early tumour shrinkage (EST) and depth of response (DpR) for the first-line treatment in patients 
with mCRC stratified based on the molecular-target agent and tumour location. EST early tumour shrinkage, 
DpR depth of response. *p value for difference between cetuximab and bevacizumab  < 0.05.
Total (n = 110)
Left-sided mCRC (n = 76) Right-sided mCRC (n = 34)
All Cetuximab (n = 36)
Bevacizumab 
(n = 40) All Cetuximab (n = 14)
Bevacizumab 
(n = 20)
EST (+), n (%) 71 (64.5) 56 (73.7) 23 (63.9) 33 (52.5) 15 (44.1) 5 (35.7) 10 (50.0)
DpR, median, 
(range) − 30.0 (− 100 to + 45) − 32.0 (− 100 to + 30)
− 43.5* (− 100 
to + 30) − 30.0* (− 64 to + 25) − 27.5 (− 100 to + 45) − 9.6 (− 100 to + 45) − 33.0 (− 58 to + 3)
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DpR. Moreover, the molecular markers influencing clinical benefit in patients with right-sided mCRCs treated 
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Figure 3.  Kaplan–Meier analyses of mCRC based on ETS. (A) OS in all patients receiving chemotherapy plus 
cetuximab or bevacizumab; (B) OS in patients with left-sided mCRCs receiving chemotherapy plus cetuximab; 
(C) OS in patients with left-sided mCRCs receiving chemotherapy plus bevacizumab; (D) OS in patients with 
right-sided mCRCs receiving chemotherapy plus cetuximab; and (E) OS in patients with right-sided mCRCs 
receiving chemotherapy plus bevacizumab. CI confidence interval, HR hazard ratio.
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There are several limitations to the present investigation. First, the patient sample size was small, particularly, 
that of the right-sided tumours, although the comparisons yielded statistical significance that strengthened our 
analysis.
Second, because this was a retrospective study, limited baseline characterisation and the heterogeneity of 
treatments in the study seemed to be a limitation; however, patient characteristics and treatment groups were 
almost comparable in left-sided and right-sided tumours. Moreover, heterogeneity as regards several molecular 
markers for the prognosis of mCRC, such as the unavailability of the BRAF status and microsatellite instability, 
could have altered the results.
Third, a large proportion of the patients treated with bevacizumab were mutant for KRAS/RAS, and this might 
have affected our analysis, especially the comparison of efficacy between left- and right-sided tumours. However, 
this effect could be of less impact since the KRAS (RAS) status of tumours was well balanced between the two 
cohorts. Finally, we may need to consider that treatment with bevacizumab may be less active in KRAS/RAS 
mutant mCRC patients, although such data are  rare32.
In conclusion, our study supports the notion that the primary tumour location is a well-known prognostic 
factor and also a relevant predictive factor in patients with mCRCs receiving cetuximab. Further, our analysis 
indicates that chemotherapy plus cetuximab may serve as the preferred option for the treatment of patients with 
RAS wt left-sided tumours to provide better OS, while the right-sided tumours presented with poor prognosis 
with all treatment measures. However, mCRC patients with right-sided tumours harbouring RAS wt status, 
who received chemotherapy plus cetuximab and achieved ETS and/or high DpR, showed better clinical benefit 
than those without ETS and low DpR. These results suggest that in patients with RAS wt right-sided mCRCs, 
bevacizumab might not be the only treatment option, and cetuximab may be considered in a subtype of mCRC, 
wherein ETS and/or high DpR can be expected.
Methods
Patients and study design. In this observational study, the medical records of 110 of 226 patients with 
pathology-documented metastatic Stage IV CRC, who underwent treatment between January 2011 and Decem-
ber 2016 at the Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan, were analysed ret-
rospectively. The study was reviewed and approved by the Ethics Committee of Hokkaido Cancer Centre (No. 
29-60), and the need for informed consent was waived. The patient records were anonymised and de-identified 
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Figure 4.  Comparison of waterfall plots showing the distribution of DpR. Waterfall plot of DpR in (A) patients 
with left-sided mCRCs receiving chemotherapy plus cetuximab; (B) patients with right-sided mCRCs receiving 
chemotherapy plus cetuximab; (C) patients with left-sided mCRCs receiving chemotherapy plus bevacizumab; 
and (D) patients with right-sided mCRCs receiving chemotherapy plus bevacizumab.
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Figure 5.  Kaplan–Meier analyses of mCRC samples based on DpR. (A) OS in all patients receiving 
chemotherapy plus cetuximab or bevacizumab; (B) OS in patients with left-sided mCRCs receiving 
chemotherapy plus cetuximab; (C) OS in patients with left-sided mCRCs receiving chemotherapy plus 
bevacizumab; (D) OS in patients with right-sided mCRCs receiving chemotherapy plus cetuximab; and (E) OS 
in patients with right-sided mCRCs receiving chemotherapy plus bevacizumab. Median DpRs were calculated as 
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ethical standards of the institution and/or national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards.
The inclusion criteria were as follows: (a) treatment with either FOLFOX or FOLFIRI plus cetuximab or beva-
cizumab; (b) patients above 20 years of age at the start of chemotherapy, with an Eastern Cooperative Oncology 
Group performance status of 0–1; and (c) adequate bone marrow reserves and renal/liver functions. Further, the 
KRAS wt or RAS wt status was considered in patients treated with cetuximab, while these statuses were neglected 
when treated with bevacizumab. The investigators evaluated the tumour response using computed tomography 
based on the guidelines of the response evaluation criteria in solid tumours (RECIST, version 1.1). The ORR 
was defined as the sum of complete and partial response, the PFS was measured from the start of chemotherapy 
until the first documented progression or death, while the OS was measured from the date of commencing 
chemotherapy until death or the date of last evaluation. Primary tumours originating in the splenic flexure, 
descending colon, sigmoid colon or rectum were classified as left-sided mCRC, whereas, those originating in 
the cecum, ascending colon, hepatic flexure or transverse colon were classified as right-sided mCRC. ETS was 
defined as the relative change in the sum of the longest diameters of the RECIST target lesions from baseline till 
the 8th Week, and a 20% decrease was set as the cut-off value to discriminate early responders (ETS ( +)) from 
non-responders (ETS (−)) as described  previously3,20,33.
DpR was defined as the percentage change in the sum of the longest diameters of the RECIST target lesions 
at the nadir in the absence of new lesions or the progression of non-target lesions compared to the  baseline3,19,20. 
DpR was evaluated as a continuous variable (i.e., each patient’s maximum percentage of shrinkage). DpR had a 
negative value for tumour reduction, positive for tumour growth, and zero for no change. These median values 
were set as cut-off points. The last follow-up date was August 25, 2020.
Statistical analysis
The Kaplan–Meier method was used to estimate PFS and OS, and these were compared with the log-rank test. A 
Cox proportional hazard model was used to calculate the hazard ratios (HR) and 95% confidence intervals (CI) 
for PFS and OS regarding the interaction between tumour origin (right or left), treatment (chemotherapy plus 
cetuximab or chemotherapy plus bevacizumab), ETS, and DpR as explanatory variables.
Fisher’s exact test was used to analyse categorical variables of patient characteristics in 2 × 2 contingency 
tables. All statistical analyses were performed using Ekuseru–Toukei 2015 (Social Survey Research Information 
Co., Tokyo, Japan). Although these were post hoc analyses, a two-sided p value < 0.05 was indicative of notable 
differences and considered statistically significant.
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